Category Archives: Transhuman News

http://www.xtracnow.com | Treat Psoriasis with Xtrac | It #39;s Your Health Radio with CEO, Dr. Dolev Rafaeli
Photomedex is a global skin health company in 55 countries with 50% of our Operations in the US. Our focus is on two things: First and biggest, Photomedex is a company that treats psoriasis in physician #39;s clinics with our Xtrac laser treatment. Second is Photomedex #39;s consumer lines (including the no!no! hair remover and Neova skincare). Most people don #39;t realize that psoriasis is an auto-immune disease. Photomedex ran a consumer-driven survey to understand the needs of those suffering psoriasis roughly two years ago. About 2 1/2% of the population suffer from Psoriasis. People are able to treat the itchiness, but were not able to find an overall solution. There is a treatment to live clear with Psoriasis: the Xtrac Laser by Photomedex. Photomedex was the first to come out with a device-based solution, the Xtrac Laser, that was the first cleared by the FDA to provide the service and solution to the patient. Exposure to UVB rays slows down or delays the growth of the skin cells that causes Psoriasis, however, an over-exposure to the sun may cause skin damage or skin cancer. The Science behind Xtrac takes the healthy aspects of UVB and focuses it ONLY on the diseased tissue. The Xtrac Laser is not painful and has no side effects. Simply visit a service-providing clinic and walk out 10 minutes later. When someone suffering with Psoriasis finishes the sessions they are able to live clear without pain, discomfort, or other side effects. The Xtrac does not CURE Psoriasis, but ...

By: xtracpsoriasis

Read more from the original source:
http://www.xtracnow.com | Treat Psoriasis with Xtrac | It's Your Health Radio with CEO, Dr. Dolev Rafaeli - Video

Stunning Cara Delevingne has shocked onlookers by taking to the catwalk with nasty-looking red patches on her legs at Milan Fashion Week.

Cara displayed the marks while modelling for Versace on Friday and it's thought that the 'wounds' are due to skin condition psoriasis, which causes red scaly blotches on the skin.

'Be gone psoriasis, you're no fun!' Cara, 20, Tweeted on Saturday.

She soon had her fans' support though, with one follower re-Tweeting Cara's message and jokingly adding: "As fun as cystitis!"

Psoriasis can be made worse by stress, drinking and smoking.

Model-of-the-moment Cara has fitted a lot of partying into her schedule recently.

Harry Styles' ex, who put in a number of appearances at London Fashion Week last week, was spotted taking a tumble down some stairs on Tuesday following a partying marathon with BFF Rita Ora.

SEE PICTURES Harry Styles in Celebrity tattoos

SEE PICTURES One Direction star Harry Styles and Taylor Swift hold hands on date in New York

SEE PICTURES Harry Styles and One Direction appear on US TV show Late Show With David Letterman in New York

Original post:
Harry Styles' ex Cara Delevingne models on catwalk with scabby red patches on legs and Tweets about psoriasis problems

WENN

Cara Delevingne is the model of the moment, having made an impressive run at London Fashion Week with her non-stop partying antics and her super-glamorous appearance on the catwalks for Burberry, Matthew Williamson, Topshop and Mulberry but it's not all as glam as we once thought, as she suffers quite badly from psoriasis.

The young beauty, who has been in Milan for fashion week this weekend, has tweeted about her frustrations, as she wrote: "Be gone psoriasis, you're no fun!", before retweeting a fan's come which said it was "about as much fun as cystitis".

Cara Delevingne Suffering From Psoriasis As Red Blotches Make Appearance At Milan Fashion Week

Cara makes a stunning appearance for Matthew Williamson (Wenn)

Our backstage insider from Burberry has told us that Cara was quite happy to stand there "stark naked" at London Fashion Week, while she was "caked in foundation", all over her body to hide the red blotches.

Over the weekend, the Mail Online published pictures of Cara modelling for Versace in a stunning red gown but were surprised to see the "angry, red blemishes", on the 20-year-old's legs.

Like a trooper, it seems that the psoriasis was left uncovered for her appearance on the catwalk. The skin condition, which has no known cure, causes red scaly patches and can be inflammed by stress, smoking, drinking and other triggers.

Other celebrity suffers include Kim Kardashian, Kris Jenner, LeAnn Rimes, as well as fellow model CariDee English.

Check out the beautiful Cara at work

Read more from the original source:
Cara Delevingne Suffering From Psoriasis As Red Blotches Make Appearance At Milan Fashion Week

BURLINGTON, Mass., Feb. 25, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today the initiation of an Investigator-Initiated Study (IIS) evaluating TSO (Trichuris suis ova or CNDO-201) for the treatment of psoriasis. The first site initiated in the multicenter study is the Icahn School of Medicine at Mount Sinai (ISMMS). Dr. Mark G. Lebwohl, Sol and Clara Kest Professor and Chairman of the Department of Dermatology, is the Principal Investigator of the trial at ISMMS.

"We are excited to be working with Mount Sinai and Professor Lebwohl, a renowned thought leader, in our pursuit of potential treatments of diseases for our lead program, TSO, where the hygiene hypothesis and immunology are important for their basic epidemiology," said Dr. Karin Hehenberger, Executive Vice President & Chief Medical Officer of Coronado. "Psoriasis is one of these diseases with critical medical need and we believe the objective nature of the assessment of progression or worsening of this disease lends itself well to this type of pilot trial."

This trial is an open-label study designed to enroll 20 patients with moderate to severe plaque psoriasis. ISMMS is the first of three sites which the company anticipates being involved in this study. Participants will receive eight doses of either TSO 2500 or TSO 7500 orally every other week over a 16-week treatment period. The trial will evaluate the effect of TSO on clinical response of psoriasis. The primary endpoint will be the average improvement in Psoriasis Area and Severity Index (PASI) from baseline at week 16. The goal of the pilot study is to test for early safety and efficacy of TSO at two different doses.

About Psoriasis

Psoriasis (psoriasis vulgaris) is a chronic inflammatory skin disease characterized by red, scaly, raised plaques. The disease process is driven by T-cell infiltration and associated elevation in cytokine levels leading to increased cell division and aberrant differentiation, resulting in the psoriatic phenotype. Plaque psoriasis has a worldwide prevalence of 2-3%, and is a chronic, recurrent skin condition with varying degrees of severity. It is the most common autoimmune disease in the U.S. As many as 7.5 million Americans have psoriasis.

Psoriasis can profoundly impact a patient's quality of life, causing disability of physical and mental functioning comparable to other major medical diseases such as type 2 diabetes, hypertension, myocardial infarction, depression, and arthritis. It is also associated with serious co-morbidities, including psoriatic arthritis, depression, malignancy, metabolic syndrome, cardiovascular morbidity and mortality. While many patients with mild disease are able to control psoriasis symptoms with topical medications alone, patients with moderate to severe disease usually require treatment with systemic agents to achieve good clearance. These systemic agents are usually well tolerated, but can have potentially significant side effects including organ toxicity, infection, malignancy, and teratogenicity that limit their usefulness in the long-term management of psoriasis.

Biologic agents have been a significant advancement in the treatment of moderate to severe psoriasis, but can have limited and/or diminishing efficacy and require administration by subcutaneous injection or intravenous infusion. These agents are still relatively new and long term safety issues (e.g., infection including tuberculosis, malignancies including lymphoma, and demyelinating neurologic events) are not fully understood. Despite all the available treatments, there is still a need for therapies that will provide high continuous efficacy, improved safety, and a more convenient route of administration to maximize compliance and satisfaction with treatment, leading to decreased burden of the disease.

About TSO

TSO (Trichuris suis ova or CNDO-201), the microscopic eggs of the porcine whipworm, is a novel, orally administered, natural immunomodulator that regulates T-Cells and pro-inflammatory cytokines. The use of TSO as a therapeutic is based on the "hygiene hypothesis" and numerous animal and human studies. TSO was chosen as the biological agent of choice because it is not a human pathogen, and is spontaneously eliminated from the body within several weeks after dosing.

In February 2012, the company reported positive results from a phase 1 clinical study of TSO in patients with Crohn's disease, where TSO was shown to be safe and well tolerated. The phase 1 trial was a multi-center, sequential dose, dose-escalation, double-blind, placebo-controlled study of 36 patients with Crohn's disease. In August 2012, Coronado initiated TRUST- I (TRichUris Suis ova Trial), a phase 2 clinical trial of TSO in patients with Crohn's disease in the United States, which is expected to be completed in the second half of 2013.

Follow this link:
Coronado Biosciences Announces Initiation of Investigator-Initiated Study Evaluating TSO in Psoriasis